ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

With the advent of new agents targeting CD20, Bruton’s tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cang, Shundong, Iragavarapu, Chaitanya, Savooji, John, Song, Yongping, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654800/
https://www.ncbi.nlm.nih.gov/pubmed/26589495
http://dx.doi.org/10.1186/s13045-015-0224-3
_version_ 1782402101863776256
author Cang, Shundong
Iragavarapu, Chaitanya
Savooji, John
Song, Yongping
Liu, Delong
author_facet Cang, Shundong
Iragavarapu, Chaitanya
Savooji, John
Song, Yongping
Liu, Delong
author_sort Cang, Shundong
collection PubMed
description With the advent of new agents targeting CD20, Bruton’s tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies. ABT-199 (venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for relapsed or refractory CLL with 17p deletion. In this review, we summarized the latest clinical development of ABT-199/venetoclax and other novel agents targeting the BCL-2 proteins.
format Online
Article
Text
id pubmed-4654800
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46548002015-11-22 ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development Cang, Shundong Iragavarapu, Chaitanya Savooji, John Song, Yongping Liu, Delong J Hematol Oncol Review With the advent of new agents targeting CD20, Bruton’s tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies. ABT-199 (venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for relapsed or refractory CLL with 17p deletion. In this review, we summarized the latest clinical development of ABT-199/venetoclax and other novel agents targeting the BCL-2 proteins. BioMed Central 2015-11-20 /pmc/articles/PMC4654800/ /pubmed/26589495 http://dx.doi.org/10.1186/s13045-015-0224-3 Text en © Cang et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Cang, Shundong
Iragavarapu, Chaitanya
Savooji, John
Song, Yongping
Liu, Delong
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
title ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
title_full ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
title_fullStr ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
title_full_unstemmed ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
title_short ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
title_sort abt-199 (venetoclax) and bcl-2 inhibitors in clinical development
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654800/
https://www.ncbi.nlm.nih.gov/pubmed/26589495
http://dx.doi.org/10.1186/s13045-015-0224-3
work_keys_str_mv AT cangshundong abt199venetoclaxandbcl2inhibitorsinclinicaldevelopment
AT iragavarapuchaitanya abt199venetoclaxandbcl2inhibitorsinclinicaldevelopment
AT savoojijohn abt199venetoclaxandbcl2inhibitorsinclinicaldevelopment
AT songyongping abt199venetoclaxandbcl2inhibitorsinclinicaldevelopment
AT liudelong abt199venetoclaxandbcl2inhibitorsinclinicaldevelopment

Ejemplares similares